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Human cytomegalovirus (HCMV) is a human herpesvirus which causes little or no disease in the immunocompetent. However, in
immunocompromised individuals, neonates, or patients on immune suppressive therapies, HCMV can cause significant morbidity
and mortality in some patient groups. As with all herpesviruses, HCMV has two life cycle phases: a productive phase, where new
virions are produced and a latent phasewhere there is a restricted gene transcription profile andnonewvirion production.Currently
available antivirals target the productive phase of HCMV infection and, although these have greatly decreased the severity of
HCMV-induced disease in immunocompromised or immunosuppressed individuals, they oftenhave associated toxicities, routinely
result in selection of drug resistant viral mutants, and, importantly, they do not target cells latently infected with virus. Thus, there
is a real need to derive novel antiviral therapies which, not least, are also able to target latent infection. In this paper, we describe
recent work which has begun to analyse changes in the cell associated with latent infection and the possibility that these latency-
associated changes in cell phenotype could be targeted by novel chemo- or immunotherapeutic strategies in order to diminish, or
even clear, latent infection at least in some specific clinical settings.
1. Review of the Literature and
the Development of Tissue Culture
Latency Models
1.1. Epidemiology and Clinical Aspects. Human cytom-
egalovirus (HCMV) is a pathogen that can cause significant
morbidity andmortality, particularly in the immunocompro-
mised host [1–10]. For instance, HCMV disease is regularly
seen after infection of individuals with a suppressed immune
system, such as transplant patients or those suffering from
AIDS. In such individuals, HCMV-associated pathology is
observed in a range of tissues and can lead to an array of
diseases including retinitis and pneumonitis as well as bowel
and heart disease ([1, 3, 4, 10] and see Figure 1). Similarly,
infection in utero, in the developing immunonaive foetus,
can result in mental retardation, deafness, and blindness [5–
9] which impact substantially QUALYS (quality adjusted life
years) measurements and, for these reasons, HCMVhas been
named as a high vaccine priority [11].
In the immunocompetent host, however, primaryHCMV
infection rarely causes disease and this is likely due to
the well-established robust immune response to the virus.
Indeed, in the developed world, 50–90% of populations can
be HCMV seropositive (and this can be as high as 100%
in some populations in the developing world), yet HCMV
disease is rarely a problem in otherwise healthy seropositive
carriers.
Despite this rigorous host immune control, HCMV is
never cleared after primary infection but persists for the
lifetime of the host which is facilitated by the ability of
the virus to establish a latent infection during which time
virus is carried silently in certain cell types in the absence
of new virion production [12]. A consensus view is that, in
healthy carriers, latent virus is able to periodically reactivate
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Figure 1: HCMV-induced disease pathology. HCMV causes disease
in individuals where the immune system is compromised. Mental
retardation, deafness, and blindness can occur following in utero
primary infection [5–8]. Retinitis occurs following primary infec-
tion and reactivation in AIDS patients [23]. Pneumonitis, hepatitis,
nephritis, and gastroenteritis/colitis can occur following immune
suppression [1, 4, 10, 18, 24, 25]. HCMV has also been suggested to
play a role in atherosclerosis and glioma progression [13, 16, 17, 20,
21, 26–28].
but, in these immunocompetent individuals, these reactiva-
tion events are also subclinical. However, it has also been
suggested that this may not be totally unproblematic as
there is increasing evidence associating HCMV persistence
with long-term diseases (i.e., atherosclerosis, chronic graft
rejection, and, perhaps, neoplasias) and reactivation of latent
HCMV is likely to be a major source of virus contributing to
its long-term carriage [13–22].
In some clinical settings, however, virus reactivation can
add substantially to disease burden. For instance, in both
solid organ and stem cell transplantation scenarios, when
recipients are heavily immunosuppressed, reactivation of the
transplant recipient’s own virus or, indeed, reactivation of
virus from donor material can lead to life threatening disease
[29, 30].
Current antiviral therapies have clearly resulted in dra-
matically improved outcomes in, for instance, transplant
patients. However, the usefulness of these drugs is often
limited by poor bioavailability, associated toxicities, and
the development of virus resistance. Similarly, so far, an
effective vaccine for the prevention of HCMV infection
remains elusive, although some success has been obtained
with posttransplant vaccination based on attenuated virus,
viral subunits, or plasmid DNA which have been shown to
reduce the duration of viraemia and requirement for antiviral
treatment in some transplant settings [31–33]. Thus, a need
for more effective vaccines or better drug treatments for
HCMV-associated disease, particularly after reactivation, is
of paramount importance. For these reasons, unraveling the
mechanisms bywhichHCMVmaintains life-long persistence
and translating this knowledge into novel strategies to target
latent infection therapeutically are of real importance.
1.2. General Molecular Biology. HCMV is the prototypic
member of the betaherpesvirus subfamily with a large
genome of around 230 kb.This is known to encode an array of
genes which interdict in numerous normal cellular functions
to ensure efficient infection and life-long persistence resulting
in a complex life cycle with multiple interactions between the
virus and its host.
Following primary infection with HCMV, two outcomes
can ensue.The virus can enter the lytic phase of replication in
which the viral transcription programme is extensive across
the whole of the genome and comprises a temporal cascade of
expression of the viral major immediate early genes followed
by early then late gene expression. This programme of lytic
transcription leads to release of infectious virions and can
occur in an array of cells and tissues in vivo [29, 42].
Alternatively, in certain cell types, the virus can enter a latent
life cycle which is associated with a much more limited viral
transcription programme and a lack of virion production
[37, 40, 43, 44]. Whilst much is known about the lytic
cycle of HCMV, the regulation of viral gene expression, as
well as virus/host interactions, during latency is less well
understood. In this review, we focus on such analyses which
are the main programme of our own research as well as a
number of other laboratories, internationally.
1.3. Latent Carriage of HCMV Occurs in Cells of the Myeloid
Lineage and Virus Can Be Reactivated uponDifferentiation. It
is now well established that one site of HCMV latency in vivo
is in cells of the myeloid lineage (Figure 2), including CD14+
monocytes and their CD34+ progenitor [29, 37, 40, 44, 49].
In these cells, likely as a concerted effect of a lack of viral
activators [39], the presence of latency-associated repressors
[40], and the dominance of cellular transcriptional repressors
of the MIEP [34, 35, 38, 50], the chromatin around the
viral MIEP becomes heavily repressive which suppresses lytic
transcription (Figure 2) and maintains latent infection [36,
37]. Following differentiation into macrophages or dendritic
cells (DCs), however, changes in the nuclear environment
result in chromatin-mediated activation of the viral MIEP
and reactivation of lytic replication [36, 37]. In the context
of an inadequate immune response (in either transplant
patients or the immunocompromised or the immunonaive),
these reactivation events then result in virus dissemination to
multiple target organs and subsequent clinical disease.
Latent viral genomes are clearly present in CD34+
haematopoietic progenitors, yet they appear to be car-
ried selectively down the myeloid lineage as they are not
detectable in T or B cells ([48] and see Figure 3). Whilst the
myeloid lineage is clearly one site of true latency of HCMV in
healthy carriers, it is yet to be determined if there are other
sites of latency in vivo. For instance, endothelial progenitor
cells have been suggested to be a potential additional site
of latency [51]. However, latent genomes are not detectable
in endothelial cells of the microvasculature which rules out
these cells as latent reservoirs [52], but it is difficult ethically
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Figure 2: HCMV latency and reactivation. Following primary infection, latency is established in the myeloid progenitor CD34+ cells which
reside in the bone marrow. Viral genome is associated with chromatin markers of repression in these cells. In particular the major immediate
early promoter (MIEP) is associated with a high number of cellular transcriptional repressors and a low number of cellular transcriptional
activators [2–4, 34–38]. This is likely to be facilitated by an absence of the viral activator pp71 [39] concomitant with the presence of
long noncoding RNA (lnr) 4.9 which is thought to interact with the polycomb repressor complex to inhibit transcription [40]. Following
differentiation along the myeloid lineage of CD34+ cells into dendritic cells (DCs), the chromatin structure at the MIEP becomes associated
with cellular activators of transcription and immediate early gene expression is induced and reactivation of the virus occurs [36, 37, 41].
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Figure 3: HCMV latency is established in myeloid progenitors and
reactivation occurs following differentiation. HCMV latency can
be established in pluripotent haematopoietic cells which can be
differentiated upon specific stimuli into different cell types as shown.
HCMV is primarily carried along the myeloid lineage [41, 46, 47]
and not the lymphoid lineage [48]. However, whether HCMV is
carried along the endothelial cell lineage is uncertain.
to interrogate endothelial cells of, for example, the macrovas-
culature from otherwise healthy donors to determine if these
cells may be additional sites of latency.
Regardless, the mechanisms which regulate the establish-
ment andmaintenance of HCMV latency in, and reactivation
from, cells of the myeloid lineage are still poorly understood
yet are crucial for a full understanding of this persistent
human pathogen.
1.4. Experimental Models of HCMV Latency in Cell Lines
and Primary Cells. Although naturally latent myeloid cells
have been used for some analyses of HCMV latent infections
[36, 40, 48, 49, 53, 54], the number of cells which carry
naturally latent viral genome is known to be extremely low
(between 1 in 10,000 and 1 in 100,000 [53]). Therefore, it has
been necessary to develop experimental models of latency
which depend on experimental infection and establishment
of latency in long-term cultures which lend themselves more
easily to analysis. In our laboratory, and others, a number
of models of experimental latency have been established for
in vitro analysis of HCMV latency and reactivation. These
include primary myeloid progenitors such as granulocyte
macrophage progenitors (GMPs) or CD34+ haematopoietic
progenitor cells as well as CD14+ monocytes [37, 49, 55–59];
all can be cultured and experimentally infected to establish
a latent infection which can be reactivated by differentiation
signals—which very much reflects models of natural latency.
Figure 4 shows an example of an experimental latency model
using primary CD34+ cells. Using this model, it has been
demonstrated that, following the establishment of latency,
the viral major immediate early promoter enhancer (MIEP)
(which drives initial expression of the major immediate early
genes (major IEs) required for lytic infection) is associated
with repressive chromatinmarkers.These includemethylated
histone marks as well as the presence of repressor proteins
such as heterochromatin protein 1 (HP1). However, following
differentiation of these cells to Langerhans-like dendritic
cells, the MIEP becomes associated with markers of active
chromatin, such as acetylated H4. Consistent with this,
expression of IE72, which is the viral major immediate
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Figure 4: Establishment of experimental latency in primary progenitor CD34+ cells and reactivation in the myeloid lineage. Following
infection of CD34+ progenitor cells with the TB40E strain of HCMV, latency is established, demonstrated by the hallmark of chromatin
repressorHP1 associationwith theMIEP in chromatin immunoprecipitation assays (ChIP): Inp= input, IgG= immunoglobulin control, AcH3
= acetylated histone H3 (marker of active chromatin), and HP1 = heterochromatin protein 1 (marker of repressed chromatin). Coculture of
these cells with fibroblasts (HFFs) does not result in IE gene expression. Untreated cells remain in a state of latency shown here for 20 days
(top). Alternatively, if after 10 days cells are differentiated andmatured into DCs, ChIP analysis shows that theMIEP becomes associated with
markers of active chromatin (AcH4) and coculture with fibroblasts shows immediate early 72-protein (IE72) gene expression. Consistent with
these observations, transcripts can be detected for the viral latent gene transcript UL138, the viral lytic gene transcript IE72, and the cellular
gene transcript GAPDH following reactivation by RT-PCR.
early (IE) protein, is silenced during latency but its expres-
sion is reactivated following differentiation. Essentially, the
same differentiation-dependent regulation of viral lytic gene
expression is observed using experimentally latently infected
CD14+ monocytes before and after their differentiation to
interstitial-like DCs. Most importantly, these observations in
experimentally latent myeloid cells fully recapitulate similar
analyses in naturally latently infected monocytes and CD34+
progenitor cells [60]. More recently, established myelomono-
cytic cells lines have also been described which can mimic
certain, but perhaps not all [61, 62], aspects of latency
observed in experimentally latent primary myeloid cells.
These include monocytic cells lines, such as THP-1 cells
[63, 64], as well as CD34+ cell lines, such as Kasumi-3 cells
[61, 65].
Regardless, it has become clear that such analyses of
experimental latent infection benefit from the use of clinical
isolates of HCMV containing full length viral genomes. In
contrast, viruses which have been extensively passaged in
fibroblasts (so-called laboratory-adapted strains) routinely
lose a 15 kb region of the genome, termed U
𝐿𝑏
󸀠 [69]. This
is known to encode at least two latency-associated gene
products [46, 59] and so may be compromised with respect
to at least some latency-associated functions.
Genomes of multiple HCMV clinical strains have now
been cloned as infectious bacterial artificial chromosomes
(BACs) and this has led to the ability to generate viralmutants
as well as fluorescently-tagged viruses which have proved to
be extremely useful in the analysis of HCMV lytic infection
and, more recently, latent infection. For a number of studies,
including our own, the use of an HCMV BAC constitutively
expressing GFP under the control of the SV40 promoter
has been useful in detecting cells carrying latent virus [65].
Similarly, a recently described clinical isolate of HCMV in
which the viral major immediate early 2 protein is fused to
a GFP tag [70] has been used to detect reactivation after
terminal differentiation of myeloid cells [62].
2. The Use of Experimental Models of
HCMV Latency to Understand Changes That
Occur in the Cell
During latent infection the viral MIEP is heavily suppressed
by histone posttranslational modifications essentially pre-
venting lytic infection. However, a number of analyses using
ex vivo naturally latent, as well as in vitro experimentally
latent, model systems have identified latency-associated tran-
scription of a number of specific viral genes (Figure 5).Whilst
the function of many of these viral genes during latency is
far from clear, recent studies have posited potential roles for
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Table 1: Cellular miRNAs are regulated during HCMV latency.
Following the establishment ofHCMV latency in CD34+ progenitor
cells, cellular miRNA analysis was carried out using the Invitrogen
NCode system [45] which identified a small number of changes.
MicroRNA Fold change during latencycompared to mock 𝑃 value
hsa-miR-let-7a −2.5 0.005
hsa-miR-let-7b −3.7 0.0001
hsa-miR-206 −2 0.02
hsa-miR-296 3p −2.6 0.007
hsa-miR-297 −2.9 0.001
hsa-miR-32∗ −2 0.07
hsa-miR-608 −2.4 0.008
hsa-miR-92a −2.5 0.003
some of these viral gene products during latent infection
[49, 71–73].
Whilst our own work using established experimental
latency protocols has contributed to such studies on latency-
associated viral gene expression [49, 71, 72], we have also anal-
ysed a number of changes in cellular gene expression during
latent infection [45, 78].These have included changes in total
cellularmicroRNAs associatedwith latency as well as changes
in secreted cellular proteins resulting from latent infection
(the latency-associated secretome). All these, we believe, are
likely to have importance for efficient latent carriage and/or
reactivation.
2.1. Latency-Associated Changes in Cellular miRNAs Can
Affect the Cellular Transcriptome . MicroRNAs (miRNAs) are
now accepted to be important posttranscriptional regulators
of cellular gene expression which act in concert to fine
tune expression of target genes. As many miRNAs can have
multiple targets, they also represent an expedient and efficient
way of coordinately regulating gene expression. For this
reason, we analysed the total cellular miRNA profile of
experimentally latent primary CD34+ cells and identified
a number of changes accompanying latency ([45] and see
Table 1).
One of the identified miRNAs which was dysregulated
during HCMV latency using an experimental latency system
with primary CD34+ cells was hsa-miR-92a (Table 1) which
was routinely downregulated during latent infection. Inter-
estingly, this latency-associated downregulation of hsa-miR-
92a resulted in the upregulation of cellular GATA2, a known
target of hsa-miR-92a (Figure 6). GATA2 is a cellular tran-
scription factor important for the regulation of hematopoiesis
in the myeloid lineage and is argued to be important as
a master switch involved in helping drive myelopoiesis
[74–76, 79, 80]. Since HCMV establishes latency in the
myeloid lineage, it has been hypothesised that this increase
in GATA2 expression during latency may aid latent carriage
[45, 46].
Not only is it likely that the latency-associated increase
in GATA2 impinges on cellular gene expression associated
with myelopoiesis but, as there are a number of predicted
GATA2 binding sites in the promoters of predicted latency-
associated transcripts such as LUNA, it is also involved in
the concomitant regulation of viral latent gene expression
[46, 49]. Interestingly, in contrast to the LUNA promoter,
GATA2 binding sites in the promoter of another latency-
associated transcript, UL144, are only present in some clinical
isolates of virus. In these isolates which do not carry GATA2
binding sites in the UL144 promoter, UL144 is not detectable
during experimental latent infection ([46] and Figure 6).
This suggests that, at least for some viral isolates, specific
latency-associated gene expression may be isolate specific
[46]. Besides the known role of GATA2 in myelopoiesis,
GATA2 can also drive the expression of other cellular genes,
including cellular IL-10 (cIL-10) (Figure 6), which is discussed
further in the next section.
2.2. Changes in the Cellular Secretome in Response to HCMV
Latency. As already discussed above, changes in a small
number of cellular miRNAs could have profound effects
on the expression of multiple cellular proteins. Studies
on the latency-associated secretome from experimental
latency using primary CD34+ cells have identified significant
increases in a number of cellular proteins secreted during
latent infection [78]. Although the mechanism by which
many of these are upregulated has yet to be determined, one
cytokinewhich has been analysed in somedetail is cIL-10 and,
as shown in Table 1 and Figure 6, its upregulation is mediated
by hsa-miR-92a via GATA2 [45].
Our recent work has shown that this increased secretion
of cIL-10 during latency has two discernible effects: (i) it
leads to prolife signalling [45] and (ii) it aids suppression
of CD4+ T cell effector functions [78] in latently infected
CD34+ cells. It is becoming clear that latent infection is a
far more active process than first believed and that latency-
associated viral gene expression leaves a distinct signature
on the latently infected cell, at least in experimental models
of latency in primary myeloid cells. Consequently, the estab-
lished argument that latent infection is essentially invisible to
the adaptive arm of the host immune response is likely to be
far from true. Indeed, our work and others have shown that
a number of latency-associated viral proteins are targets for
the host cytotoxic T cell (CTL) response [72, 81]. However, in
our hands, the T cells that are specific for these viral antigens
appear to be cIL-10 and TGF-beta secreting cells—essentially
of T suppressor phenotype [72].The observation that latently
infected cells also secrete high levels of both cIL-10 and TGF-
beta suggests that the latent microenvironment is heavily
immunosuppressive due to the latency-associated secretome
[78]. Besides an effect on inhibition of CD4+ T cell effector
function, this latency-associated increase in cIL-10 also has
profound prolife effects on CD34+ cells by preventing FAS-
mediated killing [45].
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Figure 5: HCMV genes expressed during latency. The HCMV
genome is comprised of two terminal repeats (TR), two internal
repeats (IR), a unique long region (UL), and a unique short region
(US). Genes expressed during latency identified so far are boxed and
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regions of the genome. The region of the genome termed U
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a segment of UL which becomes lost during extensive passaging
of laboratory strains and two genes identified during latency are
located in U
𝐿𝑏
󸀠 UL144 [46] and UL138 [59].
3. Understanding Latency-Associated Changes
Could Allow the Development of Novel
Strategies to Target HCMV Latency in the
Clinical Setting
3.1. Targeting of the HCMV Latently Expressed Protein UL138.
Our increased understanding of the role of viral gene prod-
ucts during latency, fromanalyses in experimental and ex vivo
latency model systems, has now led to the possibility that
these may be the basis for novel chemo- or immunothera-
peutic targets with a view to clearing latency [71] with the
important caveat that the principles established in latency
models are transferrable to the in vivo setting.
Similarly, such interventions would be made all the more
powerful when performed in conjunction with biomarkers
for latent infection. At present, such biomarkers specifically
for latency are limited but could include quantitation of
latent load in circulating monocytes by quantitative PCR or,
perhaps, frequency of circulating HCMV-specific T cells in
the peripheral blood compartment on the basis that high T
cell frequencies tomurine cytomegalovirus aremaintained by
constant restimulation with reactivating virus [82].
An understanding of how one latency-associated viral
gene, UL138, impacts cellular gene expression has recently led
to the ability to target and kill latently infected cells in both
experimental and natural latency. In these studies the effects
of expression of UL138 on total cellular plasma-membrane
associated proteins in monocytic cells were comprehensively
analysed by stable isotope labelling with amino acids in cell
culture (SILAC) [71]. Amongst the most robust changes in
cellular protein expression resulting from UL138 expression
was the downregulation of the multidrug resistance protein 1
(MRP-1) [71]. Aside from its function as a drug transporter,
MRP-1 is also associated with the regulation of myeloid
differentiation and dendritic cells (DCs) [83, 84]. Although a
role for the downregulation of MRP-1 during HCMV latent
infection is far from clear, the drug transporter function
of this cellular protein makes it a reasonable target for
intervention in latency with potential for experimental inves-
tigation using specific drugs [71]. In myeloid cells, MRP-1 can
function to transport toxic drugs, such as the vinca alkaloid
vincristine, out of the cell. On this basis, the downregulation
of MRP-1 in latently infected CD34+ cells should make
these cells more prone to killing with vincristine. Consistent
with this, treatment of both experimentally latently infected
CD34+ cells and naturally latent monocytes from a cohort
of seropositive donors with vincristine led to the specific
killing of latently infected cells. As expected, this also led to a
profound reduction in reactivation of virus from these drug-
treated cells [71].
Clearly, these preliminary results will clearly need ver-
ification in the clinical setting. Similarly, vincristine is a
toxic drug and might only be considered as an experimental
treatment of last resort. However, if less toxic derivatives of
vincristine could be developed which also cleared latently
infected cells experimentally, it may be that a seropositive
recipient could be prophylactically treated to clear or at least
reduce their latent HCMV load, prior to any immunosup-
pression.
Regardless, these data clearly show a robust proof of
principle that latent HCMV infection of myeloid cells results
in phenotypic changes in the cell which may make them
therapeutically targetable and opens up the possibility that
such strategies could be developed either to clear latently
infected cells from CD34+ cells prior to engraftment or to
reduce the latent load of transplant recipients pretransplant
to diminish levels of host virus reactivation upon immune
suppression.
4. Avenues for Future Investigation
The long-term aims of our laboratory have been to try to gain
a full understanding of host/pathogen interactions during
HCMV latent infection and these studies have helped to
identify a number of major changes in cell gene expression
resulting from latent carriage. Such studies have allowed
us to start developing novel therapeutic strategies to target
these latency-associated changes in cell phenotype with a
serious view to clearing latent infection, at least in some
clinical settings. It would clearly be difficult to advocate such
treatment in the healthy immune competent individual and
with other herpesviruses such as EBV it is arguable whether
this could be achieved [85] although multiple strategies have
been posited to target latent viral functions in EBV-associated
malignancies [86].However, withHCMV, these interventions
may be opportune in the context of transplant-mediated
reactivation where sufficient reduction in latent load of the
virus in the graft, or in the recipient prior to transplant, could
reduce levels of reactivation sufficiently to reduce disease in
such an immune-suppressed setting.
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Figure 6: GATA2 may be a key regulator of HCMV latency Downregulation of the human miRNA hsa-miR-92a leads to a concomitant
upregulation of the myeloid transcription factor GATA2 [45]. GATA2 is important during myeloid differentiation [74–77] and can drive the
expression of latency-associated genes UL144 and LUNA [46, 49]. GATA2 can also drive the expression of cellular IL-10 which in turn can
energize CD4+ cytotoxic T cells and act as a prolife signal for CD34+ cells [78].
As our understanding of the complexities in host-cell
interactions during HCMV latency expands, an increasing
number of latency-associated changes in the cell are likely
to be identified which may also be targetable with novel
immuno- and chemotherapeutic strategies. This may include
viral targets or targets resulting from modification of cellular
gene expression and we believe that this will allow the
possibility of targeting and clearing latent infection, at least
in some settings, which is a concept for HCMV which would
not have been thought possible a decade ago.
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